Juniper Pharma Services Strengthens Capsule Capability with Xcelodose

December 1, 2015
Pharmaceutical Technology Editors

Xcelodose provides automated processing of API directly into capsules at low doses. The expansion of Xcelodose reinforces Juniper’s early stage capsule filling capability.CDMO Juniper Pharma Services, a subsidiary of Juniper Pharmaceuticals, announced that it has expanded its Xcelodose powder micro-dosing system. This move reinforces the company’s early stage capsule filling capability.

CDMO Juniper Pharma Services, a subsidiary of Juniper Pharmaceuticals, announced that it has expanded its Xcelodose powder micro-dosing system. This move reinforces the company’s early stage capsule filling capability.

Xcelodose enables Juniper to accurately fill API directly into capsules in an efficient and automated manner for first-in-human studies. The technique reduces formulation requirements and minimizes drug substance wastage. It allows clinical batches to be produced economically and precisely.

The increase usage of Xcelodose is an expansion of Juniper’s manufacturing services to meet customer demand for development services that can help progress new molecules to Phase I clinical trials quicker.

Xcelodose provides automated processing of API directly into capsules at low doses. It is suitable for highly soluble products and potent molecules. The use of the system removes the requirement for complex formulation development and allows companies to generate data on a compound in a cost effective way.

Source: Juniper Pharma Services